Background: Depression is the most common psychiatric illness in patients with end-stage renal disease (ESRD), and has been associated with increased risk of death, cardiovascular events and hospitalization in a substantial proportion of patients. Impaired quality of life (QoL) has been reported in dialysis patients and is a marker of poor outcome. We aimed to assess the prevalence of depression and QoL status among chronic hemodialysis patients. We explored the relationship between depressive symptoms and poor QoL on the one hand and sociodemographic profile, dialysis adequacy, serum chemistry, malnutrition-inflammation score (MIS) and symptom burden on the other hand. Patients and Methods: 60 chronic hemodialysis patients participated in the study between June and August 2007. They were on thrice-weekly dialysis at the Kasr El-Aini Nephrology and Dialysis Center, Cairo University Hospital. Clinical and sociodemographic data were obtained and their case records were reviewed to obtain laboratory results including hemoglobin, urea reduction ratio, serum albumin, calcium, phosphorus, creatinine and total iron-binding capacity. We used the Beck Depression Inventory (BDI) to assess the severity of depression, and the SF-36 questionnaire to assess QoL in the study group. MIS was used to assess the extent of malnutrition and inflammation complex and total symptom burden was evaluated using the dialysis symptom index (DSI). Results: Mean age was 46.13 ± 16.55 years, with a range of 22–77 years. 20 patients (33.33%) had a BDI score of ≧15. Two patients (3.33%) had a QoL total score of <50, 8 (13.33%) had scores in the range of 50–60, 30 (50%) had scores in the range of 60–70, 12 (20%) had scores of 70–80, and 8 patients (13.3%) had scores in the range of 80–90. Employment was found to significantly affect BDI scores; all patients with BDI scores ≧15 were unemployed. The mean BDI score of unemployed patients was significantly higher than employed patients (13.03 ± 6.27 vs. 8.50 ± 3.51, p = 0.03). Widowed patients had significantly higher BDI and lower F-36 scores compared to single, married and divorced patients (p < 0.05). DSI and MIS showed significant positive correlations with BDI scores (p < 0.05) and significant negative correlations with F-36 scores (p < 0.05). Conclusions: Our results showed a high prevalence of depressive symptoms among the study group that was linked to poor QoL, total symptom burden and malnutrition-inflammation complex.

Keywords:
Depression, Quality of life, Malnutrition, Inflammation, Hemodialysis
1.
Kimmel PL: Psychosocial factors in dialysis patients. Kidney Int 2001;59:1599–1613.
2.
Kimmel PL, Weihs KL, Peterson RA: Survival in hemodialysis patients: the role of depression. J Am Soc Nephrol 1993;4:12–27.
3.
Smith MD, Hong BA, Robson AM: Diagnosis of depression in patients with end-stage renal disease. Comparative analysis. Am J Med 1985;79:160–166.
4.
Boulware LE, Liu Y, Fink NE, Coresh J, Ford DE, Klag MJ, Powe NR: Temporal relation among depression symptoms, cardiovascular disease event, and mortality in end-stage renal disease: contribution of reverse causality. Clin J Am Soc Nephrol 2006;1:496–504.
5.
Lopes AA, Bragg J, Young E, Goodkin D, Mapes D, Combe C, Piera L, Held P, Gillespie B, Port FK: Dialysis Outcomes and Practice Patterns Study (DOPPS): depression as a predictor of mortality and hospitalization among hemodialysis patients in the United States and Europe. Kidney Int 2002;62:199–207.
6.
Knight EL, Ofsthun N, Teng M, Lazarus JM, Curhan GC: The association between mental health, physical function and hemodialysis mortality. Kidney Int 2003;63:1843–1851.
7.
Mapes D, Lopes AA, Satayathum S, McCullough K, Goodkin D, Locatelli F, Fukuhara S, Young E, Kurokawa K, Saito A, Bommer J, Wolfe R, Held P, Port F: Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int 2003;64:339–349.
8.
Stull D, Clough L, Van Dussen D: Self-report quality of life as a predictor of hospitalization for patients with LV dysfunction. A life course approach. Res Nurs Health 2001;24:460–469.
9.
Siegrist J: Impaired quality of life as a risk factor in cardiovascular disease. J Chronic Dis 1987;40:571–578.
10.
Valderrabano F, Jofre R, Lopez-Gomez JM: Quality of life in end-stage renal disease patients. Am J Kidney Dis 2001;38:443–464.
11.
Arogundade F, Abd-Essamie M, Barsoum R: Health-related quality of life in emotionally related kidney transplantation: deductions from a comparative study. Saudi J Kidney Dis Transplant 2005;16:311–320.
12.
Patel S, Shah V, Peterson R, Kimmel PL: Psychosocial variables, quality of life, and religious beliefs in ESRD patients treated with hemodialysis. Am J Kidney Dis 2002;40:1013–1022.
13.
Peterson R, Kimmel PL, Sacks C, et al: Depression, perception of illness and mortality in patients with end-stage renal disease. Int J Psychiatry Med 1991;21:343–354.
14.
Watnick S, Kirwin P, Mahnensmith R, Concato J: The prevalence and treatment of depression among patients starting dialysis. Am J Kidney Dis 2003;41:105–110.
15.
Hedayati S, Bosworth H, Kuchibhatla M, et al: The predictive value of self-reported scales compared with physicians diagnosis of depression in hemodialysis patients. Kidney Int 2006;69:1662–1668.
16.
Ware JE, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). 1. Conceptual framework and item selection. Med Care 1992;30:473–483.
17.
McHorney CA, Ware JE, Raczek AE: The MOS 36-item short-form health survey (SF36). 2. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247–263.
18.
Edgell ET, Coons SJ, Carter WB, et al: A review of health-related quality of life measures in end-stage renal disease. Clin Ther 1996;18:887–938.
19.
Ware JE, Gandek B for the IQOLA Project: Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol 1998;51:903–912.
20.
Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH: Association among SF-36 quality of life measures, and nutrition, hospitalization, and mortality in hemodialysis. J Am Soc Nephrol 2001;12:2797–2806.
21.
Weisbord SD, Fried LF, Unruh ML, Kimmel PL, Switzer GE, Fine MJ, Arnold RM: Associations of race with depression and symptoms in patients on maintenance haemodialysis. Nephrol Dial Transplant 2007;22:203–208.
22.
Kalantar-Zadeh K, Kopple JD, Block G, Humphreys M: A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis 2001;38:1251–1263.
23.
Henderson AS, Jorm AF, Korten AE, et al: Symptoms of depression and anxiety during adult life: evidence for a decline in prevalence with age. Psychol Med 1998;28:1321–1328.
24.
Mingardi G, Cornalba L, Cortinovis E, Ruggiata R, Mosconi P, Apolone G: Health-related quality of life in dialysis patients. A report from an Italian study using SF-36 health survey. Nephrol Dial Transplant 1999;14:1503–1510.
25.
Kalantar-Zadeh K, Kopple JD: Relative contributions of nutrition and inflammation to clinical outcome in dialysis patients. Am J Kidney Dis 2001;38:1343–1350.
26.
Abdullah MS, Wild G, Jacob V, et al: Cytokines and the malnutrition of chronic renal failure. Miner Electrolyte Metab 1997;23:237–242.
27.
Yeun JY, Kaysen GA: Factors influencing serum albumin in dialysis patients. Am J Kidney Dis 1998;32(suppl 4):S118–S125.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.